INO icon

Inovio Pharmaceuticals

1.58 USD
-0.07
4.24%
At close Updated Mar 20, 4:00 PM EDT
Pre-market
After hours
1.62
+0.04
2.53%
1 day
-4.24%
5 days
-5.39%
1 month
-8.67%
3 months
-29.78%
6 months
-36.55%
Year to date
-6.51%
1 year
-18.56%
5 years
-98.72%
10 years
-98.18%
 

About: Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Employees: 134

0
Funds holding %
of 8,088 funds
Analysts bullish %
0
Positive news %
Price charts implemented using Lightweight Charts™